10Jul
Proactive Due Diligence Considerations for Life Sciences Dealmakers
In today’s competitive and fast-paced life sciences dealmaking environment, buyers and investors are often unable to spend as much time on due diligence as they might like. Market players are often highly focused on the science itself and, as a...
By:
McDermott Will & Emery
Related
This week, in response to the emergence of COVID-19 hot spots in downstate New York, Governor Cuomo ...
Read More >
The Employee Benefits Practice is pleased to present the Employee Benefits Developments Newsletter f...
Read More >
Act No. 2 of October 17, 1961 (Act 2) created a procedural process for the expeditious adjudication ...
Read More >
On October 13, 2019, California Governor Gavin Newsom signed into law Assembly Bill 51 (“AB 51”). ...
Read More >
As its session draws to a close, the New York State Legislature substantially revised the state’s a...
Read More >
In Dutra v. Batterton, No. 18-266, the Supreme Court of the United States, on June 24, 2019, determi...
Read More >